Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TolaSure topical gel - BioMendics

Next Previous
Drug Profile

TolaSure topical gel - BioMendics

Alternative Names: BM-3103; TolaSure; TolaSure topical gel

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMendics
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antifungals; Antivirals; Small molecules
  • Mechanism of Action Bacterial biofilm inhibitors; Bacterial growth inhibitors; Intermediate filament protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epidermolysis bullosa; Wounds
  • Preclinical Bacterial infections; Burns; Dermatitis; Ichthyosis; Methicillin-resistant Staphylococcus aureus infections; Mycoses; Psoriasis; Scleroderma; Skin ulcer

Most Recent Events

  • 18 Jun 2025 Phase-II clinical trials in Epidermolysis bullosa in USA (Topical) (NCT07027345)
  • 28 May 2025 No recent reports of development identified for phase-I development in Epidermolysis-bullosa in USA (Topical, Gel)
  • 30 Oct 2023 BioMendics plans a phase II trial for Epidermolysis bullosa (Topical) in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top